Last reviewed · How we verify

Tetec AG — Portfolio Competitive Intelligence Brief

Tetec AG pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NOVOCART® Inject plus NOVOCART® Inject plus phase 3 Autologous cell therapy Orthopedics / Rheumatology
NOVOCART® 3D plus NOVOCART® 3D plus phase 3 Autologous cell therapy Orthopedics / Regenerative Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Cook MyoSite · 1 shared drug class
  2. GC Cell Corporation · 1 shared drug class
  3. Seoul National University Bundang Hospital · 1 shared drug class
  4. Sewon Cellontech Co., Ltd. · 1 shared drug class
  5. StemCyte, Inc. · 1 shared drug class
  6. TiGenix n.v. · 1 shared drug class
  7. UnicoCell Biomed CO. LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tetec AG:

Cite this brief

Drug Landscape (2026). Tetec AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tetec-ag. Accessed 2026-05-13.

Related